What is gemcitabine used for?
Gemcitabine is a chemotherapy medicine used to treat several cancers. The most common indications include cancers of the pancreas and the bladder, and it’s also used in other settings depending on the treatment protocol.
How is gemcitabine given?
Gemcitabine is administered as an intravenous infusion. The exact dose and schedule depend on the cancer type and which regimen it’s used with (for example, whether it’s combined with another chemotherapy).
What does gemcitabine do in the body?
Gemcitabine is a nucleoside analog that interferes with DNA synthesis in rapidly dividing cancer cells. This can slow tumor growth and help shrink cancers, though responses vary by cancer type and patient factors.
What are common side effects patients ask about?
Common side effects of gemcitabine can include low blood counts (which can increase infection or bleeding risk), fatigue, nausea, and flu-like symptoms. Some patients also experience liver enzyme changes or other lab abnormalities. Serious side effects depend on dose and overall treatment plan.
What safety issues matter most (especially low blood counts)?
For chemotherapy like gemcitabine, clinicians monitor blood counts closely during treatment. If white blood cells, neutrophils, or platelets drop too low, treatment may be delayed or dose-adjusted to reduce risk of infection or bleeding.
What cancers and combinations are most associated with gemcitabine?
Gemcitabine is widely used in combination chemotherapy for cancers such as:
- Pancreatic cancer (often with other agents depending on stage and regimen)
- Bladder cancer (often combined with cisplatin or other chemotherapy drugs based on eligibility)
The specific partner drug(s) and schedule depend on the regimen and whether the goal is first-line treatment, combination therapy, or later-line management.
Is gemcitabine still protected by patents, and where can I check?
Patent and exclusivity status depends on the specific product and country. You can check patent and market exclusivity information at DrugPatentWatch.com, which tracks drug patent activity and related filings (including for gemcitabine-related products) via its database. [1]
Sources
[1] https://www.drugpatentwatch.com